Written Question·Department of Health and Social Care·UIN 78986
Trastuzumab Deruxtecan
Tabled: 10 October 2025
Answered: 21 October 2025
Question
Max Wilkinson
Liberal Democrat — Cheltenham
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's decision to restrict secondary breast cancer patient's access to Enhertu on the grounds of patient wellbeing.
Answer
Dr Zubir AhmedThe National Institute for Health and Care Excellence (NICE) makes independent, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded for eligible patients based on an evalua...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 78986) →